|
Indications and Dosage
Oral
Peripheral vascular disease Adult: For the treatment of cases such as intermittent claudication, night cramps, rest pain, Raynaud's syndrome, incipient gangrene, trophic ulcers, diabetic arteriopathy and acrocyanosis: 100-200 mg tid. Alternative recommended dose for Raynaud's syndrome: As tab: 200 mg bid. Dosing recommendations may vary among countries and individual products (refer to specific product guidelines).
|
|
Administration
Should be taken with food. Take w/ a large glass of water.
|
|
Contraindications
History of hyperoxaluria or recurrent Ca-containing renal stones.
|
|
Special Precautions
Renal and hepatic impairment.
|
|
Adverse Reactions
Significant: Local oesophagitis (when taken without liquid before lying down); rarely, liver damage; very rarely, Ca oxalate kidney stones.
Gastrointestinal disorders: Nausea, vomiting, epigastric pain, diarrhoea. Skin and subcutaneous tissue disorders: Rash. |
|
Patient Counseling Information
Administer with an adequate amount of fluid, particularly if taken before lying down. Ensure sufficient fluid intake during treatment to reduce the risk of kidney stones.
|
|
Overdosage
Symptoms: Convulsions, depression of cardiac conductions. Management: Perform gastric lavage and induce emesis. May administer activated charcoal if needed. Monitor CV function and respiration. For severe cases, may consider electrical pacemaking or administration of isoprenaline. May give diazepam for convulsions.
|
|
Action
Description: Naftidrofuryl, a 5-HT2 receptor antagonist, produces vasodilation on both peripheral and cerebral circulation. It also activates intracellular aerobic metabolism which may provide cell protection against metabolic effects of ischaemia by increasing ATP levels and reducing lactic acid levels. Furthermore, it is a potent spasmolytic agent.
Synonym: nafronyl. Pharmacokinetics: Absorption: Well absorbed. Bioavailability: 17-32%. Time to peak plasma concentration: 30-45 minutes (cap); 2-3 hours (tab). Distribution: Plasma protein binding: 92%, mainly albumin. Metabolism: Primarily metabolised via hydrolysis into inactive metabolites. Excretion: Via urine (80% as metabolites). Elimination half-life: 0.8-1.6 hours (cap); 3-4 hours (tab). |
|
Chemical Structure
 Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 4417, Naftidrofuryl. https://pubchem.ncbi.nlm.nih.gov/compound/Naftidrofuryl. Accessed June 25, 2021. |
|
Storage
Store below 25°C. Protect from moisture and light.
|
|
ATC Classification
C04AX21 - naftidrofuryl ; Belongs to the class of other peripheral vasodilators.
|
|
References
Anon. Naftidrofuryl (Nafronyl). Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 04/06/2021. Buckingham R (ed). Naftidrofuryl Oxalate. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 04/06/2021. Joint Formulary Committee. Naftidrofuryl Oxalate. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 04/06/2021. Naftidrofuryl Capsules BP 100 mg (Accord-UK Ltd). MHRA. https://products.mhra.gov.uk. Accessed 04/06/2021.
|
Sign Out
